The Importance of Human Tissue Bioresources in Advancing Biomedical Research.
The Importance of Human Tissue Bioresources in Advancing Biomedical Research. Biopreserv Biobank. 2019 Jun;17(3):209-212 Authors: Al Diffalha S, Sexton KC, Watson PH, Grizzle WE Abstract Medical research advances enabling the realization of precision medicine have relied heavily on the biospecimens provided by bioresources to identify the targets and biomarkers that are the focus of the new generation of more effective molecular-based therapies for specific subtypes of diseases. Through the biospecimens they have distributed, bioresources have permitted subtypes of cancers to be identified and molecular features of these subtypes to be effectively targeted. A prototype example is the human epidermal growth factor receptor type 2 (HER2), which currently is targeted in breast and gastric cancers. In the future, the use of biospecimens from bioresources will continue to increase the understanding of the molecular actions of drugs and how drugs may be more or less active in subpopulations of patients. Although the biospecimen inventories of the initial forms of bioresources may not have always been optimally planned and, therefore, utilized in supporting biomedical research, bioresources are evolving and overall, bioresource inventories and increasingly their prospective collection capabilities will continue to be a critical component of the research infrastructure. PMID: 31188626 [PubMed - in process]
ConclusionWe demonstrated a new approach of NIR-PIT utilizing a target on vascular endothelium, such as VEGFR-2, and this treatment might lead to the development of a new therapeutic strategy for human gastric cancer.
Conditions: Adenocarcinoma Gastric Stage IV With Metastases; Adenocarcinoma - GEJ Intervention: Drug: Trastuzumab deruxtecan Sponsor: Daiichi Sankyo, Inc. Not yet recruiting
Thomas A. Abrams Senior Physician and Assistant Professor of Medicine at Harvard Medical School tells us histhoughts on KEYNOTE-62. This is investigating pembrolizumab in HER2, PD-L1 positive advanc... Author: obr Added: 06/25/2019
Publication date: July 2019Source: The Journal of Molecular Diagnostics, Volume 21, Issue 4Author(s): Sangjoon Choi, Jinah Chu, Binnari Kim, Sang Yun Ha, Seung Tae Kim, Jeeyun Lee, Won Ki Kang, Heewon Han, Insuk Sohn, Kyoung-Mee KimIntratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) is common in gastric cancer (GC). However, a direct comparison between the results of HER2 immunohistochemistry (IHC) and next-generation sequencing (NGS)–based cancer panel tests has not been explored in GC. We aimed to determine optimal thresholds of HER2 overexpression to be detected by NGS with the data of 16...
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
In this study, we developed a novel anti-HER2 monoclonal antibody (mAb), H2Mab-41 (IgG2b, kappa), and the antitumor activity of H2Mab-41 was investigated using mouse xenograft models. Caco-2 cells (human colon cancer cell line), which expresses HER2, were subcutaneously implanted into the flanks of nude mice. H2Mab-41 and control mouse IgG were injected three times into the peritoneal cavity of mice. H2Mab-41 significantly reduced tumor development of Caco-2 xenograft in comparison with the control mouse IgG on days 5, 8, 11, 15, and 19. Taken together, these results suggest that H2Mab-41 is useful for antibody therapy aga...
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
ConclusionIn our analysis, pathological staging and primary site were main prognostic factors. Moreover, a small group of EGJ/HER2+ had very poor survival.
ConclusionsPertuzumab exposure in JACOB was consistent with prior studies in advanced gastric cancer and breast cancer. The 840 mg q3w dose allowed the majority of patients in JACOB to achieve target pertuzumab concentrations and appears to be an appropriate dose selection.